Sarcoma
Welcome,         Profile    Billing    Logout  
 557 Companies   303 Products   303 Products   167 Mechanisms of Action   1505 Trials   139130 News 


«12...15131514151515161517151815191520152115221523...18141815»
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Clinical, Journal:  Vascular modulation through exercise improves chemotherapy efficacy in Ewing sarcoma. (Pubmed Central) -  Jan 25, 2020   
    Our results support a model in which exercise remodels ES vasculature to reduce vessel hyperpermeability, potentially via modulation of S1PR1 and S1PR2, thereby improving doxorubicin delivery and inhibiting tumor growth more than doxorubicin alone does. Our data suggest moderate aerobic exercise should be tested in clinical trials as a potentially useful adjuvant to standard chemotherapy for patients with ES.
  • ||||||||||  Journal:  A unified mechanism for LLPS of ALS/FTLD-causing FUS as well as its modulation by ATP and oligonucleic acids. (Pubmed Central) -  Jan 25, 2020   
    Our results together establish a unified mechanism in which the π-cation interaction acts as the major driving force for LLPS of FUS and also serves as the target for modulation by ATP and oligonucleic acids through specific binding. This mechanism predicts that a myriad of proteins unrelated to RNA-binding proteins (RBPs) but with Arg/Lys-rich disordered regions could be modulated by ATP and nucleic acids, thus rationalizing the pathological association of Amyotrophic lateral sclerosis (ALS)-causing C9ORF72 dipeptides with any nucleic acids to manifest cytotoxicity.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Osteosarcoma journey over two decades in India: Small steps, big changes. (Pubmed Central) -  Jan 25, 2020   
    This mechanism predicts that a myriad of proteins unrelated to RNA-binding proteins (RBPs) but with Arg/Lys-rich disordered regions could be modulated by ATP and nucleic acids, thus rationalizing the pathological association of Amyotrophic lateral sclerosis (ALS)-causing C9ORF72 dipeptides with any nucleic acids to manifest cytotoxicity. Sequential selection of an intelligent, dose-dense chemotherapy regimen together with enhanced supportive care resulted in marked improvement in outcomes of nonmetastatic osteosarcoma and this "small steps-big changes" model deserves wider recognition and usage.
  • ||||||||||  iadademstat (ORY-1001) / Oryzon, GSK2879552 / GSK
    Journal:  Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. (Pubmed Central) -  Jan 25, 2020   
    Overall, evidence presented here does not support inhibition of KDM1A catalytic demethylase activity as an effective therapeutic strategy for Ewing sarcoma or DSRCT. However, roles of KDM1A beyond its demethylase activity should be considered for these sarcomas.
  • ||||||||||  Precision medicine for high-risk paediatric and AYA sarcomas (Trade Area Level 2&3) -  Jan 24, 2020 - Abstract #LCC2020LCC_72;    
    This study is one of the most comprehensive clinical efforts ever undertaken in precision medicine in advanced paediatric and AYA sarcoma. It not only provides a unique resource to study biology and therapeutic opportunities in a diverse set of rare HR sarcomas; our interim results also highlight the feasibility and clinical utility of precision medicine in HR sarcomas.
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Using patient-derived xenograft models to explore disease - a case report of uterine leiomyosarcoma (Trade Area Level 2&3) -  Jan 24, 2020 - Abstract #LCC2020LCC_63;    
    To explore the possibility of the requirement of an immune response to facilitate the efficacy of Olaparib in this particular PDX line, we have successfully transplanted the tumour into humanised NSG mice which are currently undergoing treatment. Sequencing of the PDX line is also planned to further characterise the tumour, which may provide additional benefit to the patient particularly in predicting therapy resistance.
  • ||||||||||  Using genomics and pre-clinical models to improve treatment options for patients with rare cancers (Auditorium) -  Jan 24, 2020 - Abstract #LCC2020LCC_15;    
    Two cases of rare gynaecological neuroendocrine tumours for which we have WGS and for one, a corresponding PDX, have resulted in never-responder and cell of origin studies respectively. The WEHI-SFRCP provides clinically relevant research options for those with rare cancers nation-wide, enabling matched therapies to be identified for individual patients as well as developing pre-clinical research projects to further understand specific rare cancers, underpinning new treatment options for future patients.
  • ||||||||||  Journal:  Carcinosarcoma of the hand. (Pubmed Central) -  Jan 24, 2020   
    Both components were negative for CD34 and D2-40. This tumor was found to have angiolymphatic invasion and eventually metastasized to the axillary lymph nodes and lungs.